ArsenalBio IPO

arsenalbio.com

ArsenalBio is a biotechnology company looking to develop efficacious and safe cellular therapies for patients with chronic diseases and develops cellular drug discovery tools designed to provide medicines for cancer treatment. The company's tools operate in cell genome engineering and cell manufacturing platforms, enabling hospitals to create T-cell medicines for cancer treatment.

Founded2019
Total Funding to Date$339.82MM
Register for Details

For more details on financing and valuation for ArsenalBio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

ArsenalBio Ticker Symbol

ArsenalBio does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

ArsenalBio Stock Price

The stock price for ArsenalBio will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for ArsenalBio

Kleiner Perkins
Euclidean Capital
Westlake Village BioPartners
the Parker Institute

ArsenalBio Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/6/2022 Series B and B-2 $253.81MM raised $XXX.XX $XXX.XX
10/17/2019 Series A $86.02MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like ArsenalBio in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM